6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

May 29, 2020

Commission File Number: 001 - 38178

Zealand Pharma A/S

(Exact Name of Registrant as Specified in Its Charter)

Sydmarken 11

2860 Søborg (Copenhagen)
Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x            Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ¨

Furnished as Exhibit 99.1 to this Report on Form 6-K is a company announcement of Zealand Pharma A/S or the Company, dated May 29, 2020, disclosing information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons. Exhibits 99.2, 99.3 and 99.4 provide details on these transactions.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Zealand Pharma A/S
By:	/s/ Matthew Dallas
	Name:	Matthew Dallas
	Title:	Chief Financial Officer

Date: May 29, 2020

2

EXHIBIT INDEX

Exhibit No.	Description
99.1	Company announcement dated May 29, 2020
99.2	Exercise of warrants – A. Steensberg
99.3	Sale of shares – A. Steensberg
99.4	Sale of shares – A. Steensberg

3

EX-99.1

Exhibit 99.1

Company announcement – No. 30 / 2020  

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Copenhagen, May 29, 2020 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20045078) has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.

Please see the attached files.

# # #

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of next generation peptide-based medicines that change the lives of people living with metabolic and gastrointestinal diseases. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development, and one candidate being reviewed for regulatory approval in the United States. Zealand markets V-Go^®, an all-in-one basal-bolus insulin delivery option for people with diabetes. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics.

Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit www.zealandpharma.com.

For further information, please contact:

Zealand Pharma Investor Relations

+45 50 60 38 00

investors@zealandpharma.com

Lani Pollworth Morvan, Investor Relations and Communication

LMorvan@zealandpharma.com

EX-99.2

Exhibit 99.2

 

EX-99.3

Exhibit 99.3

 

Template for notification and public disclosure of transactions by persons discharging manage-rial responsibilities and persons closely associated with them

1. Details of the person discharging managerial responsibilities/person closely associated

a) Name Adam Steensberg

2. Reason for the notification

a) Position/status EVP, Chief Medical and Development Officer in Zealand Pharma A/S

b) Initial notification/Amend- Initial notification

  ment

3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auc-

  tion monitor

a) Name Zealand Pharma A/S, CVR-no. 20045078

b) LEI¹ 549300ITBB1ULBL4CZ12

4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a) Description of the financial   Shares

  instrument, type of instru-

  ment

  Identification code   DK0060257814

b) Nature of the transaction   Sale of shares

c) Price(s) and volume(s)

  Price(s) Volume(s)

        DKK 255,00 14.962

d) Aggregated information

  - Aggregated volume   DKK 3.815.310

  - Price

e) Date of the transaction   28 May 2020

f) Place of the transaction   Nasdaq Copenhagen A/S

EX-99.4

Exhibit 99.4

 

Template for notification and public disclosure of transactions by persons discharging manage-rial responsibilities and persons closely associated with them

1. Details of the person discharging managerial responsibilities/person closely associated

a) Name Adam Steensberg

2. Reason for the notification

a) Position/status EVP, Chief Medical and Development Officer in Zealand Pharma A/S

b) Initial notification/Amend- Initial notification

  ment

3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auc-

  tion monitor

a) Name Zealand Pharma A/S, CVR-no. 20045078

b) LEI¹ 549300ITBB1ULBL4CZ12

4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a) Description of the financial   Shares

  instrument, type of instru-

  ment

  Identification code   DK0060257814

b) Nature of the transaction   Sale of shares

c) Price(s) and volume(s)

  Price(s) Volume(s)

        DKK 255,00 25.038

d) Aggregated information

  - Aggregated volume   DKK 6.384.705,20

  - Price

e) Date of the transaction   29 May 2020

f) Place of the transaction   Nasdaq Copenhagen A/S